oru.sePublikationer
Ändra sökning
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Improving the management of high cost anticancer drugs in a health care system
Hospital Pharmacy, Veneto Institute of Oncology IOV-I.R.C.C.S., Padua, Italy.
School of Specialisation in Hospital Pharmacy, Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Padua, Italy.
School of Specialisation in Hospital Pharmacy, Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Padua, Italy.
Hospital Pharmacy, Veneto Institute of Oncology IOV-I.R.C.C.S., Padua, Italy. (Nutrition Gut Brain Interactions)
Visa övriga samt affilieringar
2016 (Engelska)Ingår i: Global and Regional Health Technology Assessment, ISSN 2284-2403, Vol. 3, nr 3, s. 155-158Artikel i tidskrift (Övrigt vetenskapligt) Published
Abstract [en]

As a consequence of the rise in cancer prevalence and in the cost of anticancer drugs, global spending for cancer is increasing rapidly. The aim of this work is to identify and assess some effective cost management parameters and possible strategies to contain expenditure. Cost limitation could be achieved by implementing effective prevention measures and other main actions: diffusion of tailored therapies; systematic postmarketing reviews; cost-effectiveness assessment; accurate treatment choices; more transparent and effective managed entry agreement policies; waste management through personalized dose preparation. To better manage high cost anticancer drugs, oncologists and hospital pharmacists should collaborate in choosing the right drug, for the right patient, at the right time. In addition, besides promoting the use of biosimilars and generic drugs, when different products have a similar clinical effectiveness, a cost-minimization analysis should be performed to identify the best clinical approach at the lowest cost. With the same purpose, verifying real life outcomes by managing postmarketing analyses helps to renegotiate price agreements in a value-for-money model; this could be arranged if the regulatory agencies renegotiate the previously established price within a defined time period. Finally, the centralization of high-cost drug preparation and the implementation of a drug-day (vial sharing) will reduce drug waste.

Ort, förlag, år, upplaga, sidor
Milan, Italy: Wichtig Publishing , 2016. Vol. 3, nr 3, s. 155-158
Nyckelord [en]
Drug expenditure, managed entry agreement, oncology, preparation waste, postmarketing register
Nationell ämneskategori
Medicin och hälsovetenskap Hälso- och sjukvårdsorganisation, hälsopolitik och hälsoekonomi
Forskningsämne
Hälso- och sjukvårdsforskning; Nationalekonomi
Identifikatorer
URN: urn:nbn:se:oru:diva-65210DOI: 10.5301/grhta.5000243ISI: 000405311400006OAI: oai:DiVA.org:oru-65210DiVA, id: diva2:1185426
Tillgänglig från: 2018-02-24 Skapad: 2018-02-24 Senast uppdaterad: 2018-07-24Bibliografiskt granskad

Open Access i DiVA

Fulltext saknas i DiVA

Övriga länkar

Förlagets fulltext

Personposter BETA

Gorreja, Frida

Sök vidare i DiVA

Av författaren/redaktören
Gorreja, Frida
Medicin och hälsovetenskapHälso- och sjukvårdsorganisation, hälsopolitik och hälsoekonomi

Sök vidare utanför DiVA

GoogleGoogle Scholar

doi
urn-nbn

Altmetricpoäng

doi
urn-nbn
Totalt: 39 träffar
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf